by Ethan Faverino | Nov 10, 2025 | News
By Ethan Faverino |
Congressman Abe Hamadeh urged the Food and Drug Administration (FDA) Commissioner, Dr. Martin Makary, to immediately withdraw or indefinitely suspend enforcement actions against desiccated thyroid medications.
This follows explosive allegations of misconduct by former Center for Drug Evaluation and Research (CDER) Director George Tidmarsh.
Dr. Tidmarsh resigned on November 2, 2025, amid a Department of Health and Human Services (HHS) investigation into claims that he abused his regulatory authority to target desiccated thyroid drugs—medications safely used by 1.5 million Americans for decades—in an effort to harm business rival, Kevin Tang.
Aurinia Pharmaceuticals filed a lawsuit the same day, alleging Tidmarsh used official FDA resources to “target multiple companies” linked with Tang, including a company where Tang serves as board chairman, American Laboratories, a key supplier of active ingredients for desiccated thyroid drugs.
The timeline raises serious concerns as Tidmarsh assumed leadership of CDER in July 2025, just one month before the FDA issued enforcement warnings against these very medications.
Reports indicate Tidmarsh was placed on administrative leave on November 1st, before resigning the following day.
In Congressman Hamadeh’s first letter, he raised alarms about the FDA’s actions, warning that restrictions could disrupt care for thousands of veterans and seniors in Arizona’s 8th District who rely on these treatments. Although Hamadeh’s office followed up many times, the FDA provided a very generic response to their inquiries.
Now, in a November 4th letter to Commissioner Makary, Congressman Hamadeh demanded immediate action, including:
- Suspension of all enforcement actions against desiccated thyroid drugs initiated on or after July 2025.
- A transparent public and congressional accounting of all regulatory decisions involving thyroid medications, including communications, conflicts of interest, and internal concerns about Dr. Tidmarsh.
- 180-day advance notice to Congress before any future enforcement, with scientific justification and patient impact assessments.
- Guaranteed uninterrupted access for the 1.5 million patients dependent on these medications.
- Substantive responses to his original August inquiries.
“It was clear to me, based on the feedback that I have received from countless constituents, that the FDA’s action against these medications was likely not science-based,” said Congressman Hamadeh. “Given our government’s reaction to COVID-19, it is not hard to imagine that bad actors in our government have personal agendas and no regard for science or our citizens.”
“The FDA’s primary mission should be ensuring drug safety and efficacy, not unnecessarily restricting access to medications with established track records of safety and effectiveness,” concluded Congressman Hamadeh. “The American people expect that FDA regulatory actions be grounded in science and patient safety, not personal scores or abuse of authority.”
Ethan Faverino is a reporter for AZ Free News. You can send him news tips using this link.
by Ethan Faverino | Aug 22, 2025 | News
By Ethan Faverino |
On August 6, 2025, the Food and Drug Administration (FDA) sent letters to manufacturers, importers, and distributors of unapproved animal-derived thyroid medications, notifying them of the agency’s intent to take enforcement action due to concerns over safety, potency, and dosing consistency.
These medications, derived from dried animals’ thyroid glands, are used by an estimated 1.5 million patients in the U.S. but are not FDA-approved, unlike synthetic alternatives like levothyroxine, which serve approximately 22 million patients.
The agency has allowed a 12-month transition period for patients to switch to FDA-approved medications.
Earlier this week, Congressman Abe Hamadeh (AZ-08) issued a formal inquiry to Dr. Martin Makary, Commissioner of the FDA, seeking clarity on recent agency actions that could restrict access to desiccated thyroid medications such as Armour Thyroid, NP Thyroid, Nature-Thyroid, and Natural Thyroid, which are critical for many patients managing hypothyroidism.
In his letter to Dr. Makary, Congressman Hamadeh emphasized the concerns of his constituents, particularly the veterans and seniors in Arizona’s 8th Congressional District, who rely on desiccated thyroid medications for effective treatment.
“Many of these patients have found desiccated thyroid medications to be more effective than synthetic alternatives for managing their thyroid conditions,” said Hamadeh. “Any disruption to their treatment regimens could have serious health consequences and undermine the doctor-patient relationship.”
Congressman Hamadeh requested that the FDA provide answers by September 5, 2025, to the following questions:
- What specific actions, if any, is the FDA taking regarding desiccated thyroid medications like Armour Thyroid?
- What evidence supports any potential restrictions on these long-established medications that have been safely used for decades?
- Has the FDA conducted a comprehensive analysis of how any restrictions would affect patients who rely on these medications?
- If restrictions are being considered, what steps will the FDA take to ensure patients maintain access to effective thyroid treatment options?
Congressman Hamadeh continued to state, “This issue reflects broader concerns about federal agency overreach into medical decisions that should remain between patients and their physicians. The FDA’s primary mission should be ensuring drug safety and efficacy, not unnecessarily restricting access to medications with established track records of safety and effectiveness.”
Dr. Makary has already responded to the backlash and public concerns via X (Twitter), stating that the “FDA is committed to pursuing the first-ever approval of desiccated thyroid extract, pending results of the ongoing clinical trials. In the meantime, we will ensure access for all Americans.”
Ethan Faverino is a reporter for AZ Free News. You can send him news tips using this link.
by Matthew Holloway | Apr 3, 2025 | News
By Matthew Holloway |
Arizona Senate Majority Leader Janae Shamp, who has spearheaded a raft of medically-related legislation, hailed the confirmation of the new U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary.
Along with expressing her approval of Makary, Shamp emphasized her commitment to her “Make Arizona Healthy Again” Agenda, complementing the national policy of “Make America Healthy Again” undertaken by the Trump administration.
In a press release, the Arizona Senate GOP explained that as a perioperative nurse, Shamp “witnessed firsthand instances of corruption within the healthcare system, big companies using influence to impact state agency operations, as well as negligent government actions and overreach leading to negative health consequences for Arizonans.”
Shamp said in a statement:
“It’s time to clean up public health in our country, and Dr. Makary is the right man for the job. I am so excited to see him as our new FDA Commissioner. As an experienced surgeon, Dr. Makary has a lifetime of exceptional service in the field of health and wellness. He will undoubtedly help President Donald J. Trump and Secretary Robert F. Kennedy, Jr. carry out their goals to make America healthy again.”
She continued, “Our food supply is full of toxins and carcinogens. Americans are incredibly overmedicated. I look forward to seeing his great work at the FDA to address these critical issues, and I am proud to support the MAHA movement with state legislation that is in lockstep with the goals of the Trump Administration to create a healthier society.”
As previously reported by AZ Free News, Shamp’s bill, SB 1586, is designed to create legal protections for children and teens who have been subjected to so-called ‘gender transition procedures,’ setting the ground work for potential medical malpractice litigation. Shamp also co-sponsored HB 2164, introduced by her Rep. Leo Biasiucci, to “ban ultra-processed foods containing harmful additives from being served in public school meals.”
In addition, Shamp has also introduced or co-sponsored several healthcare reform measures including: SB 1102, to prevent insurance companies from acting as the “middleman” from “unwarranted interference in the doctor-patient relationship,” which was signed into law last week; SB 1235, protecting the State of Arizona from potential anti-trust lawsuits by restructuring health regulatory boards; and HB 2165, which would prohibit Supplemental Nutrition Assistance Program (SNAP) enrollees from purchasing soda with taxpayer funded SNAP benefits.
Matthew Holloway is a senior reporter for AZ Free News. Follow him on X for his latest stories, or email tips to Matthew@azfreenews.com.
by Corinne Murdock | Aug 19, 2023 | News
By Corinne Murdock |
The Scottsdale-based Alliance Defending Freedom (ADF) secured a federal court ruling that effectively halts mail-order abortions.
On Wednesday, the Fifth Circuit Court of Appeals ruled that the Food and Drug Administration (FDA) must reinstate its safety restrictions for mifepristone use. In effect, the ruling limits mifepristone’s use to the first seven weeks of pregnancy, as well as requires an in-person visit with a provider prior to prescription.
This is the Texas court’s second ruling against mifepristone access. In April, the court issued an injunction against the abortion drug. The same hour of that injunction, a Washington federal court ruled that the FDA must continue providing mifepristone. Several weeks after those conflicting orders, the Supreme Court halted the Texas court’s injunction until all litigation had concluded.
ADF sued the FDA last November on behalf of four pro-life medical groups, who argued that mifepristone shouldn’t have been approved by the FDA over 20 years ago and should be removed from the market.
The FDA approved mifepristone in 2000, during the Clinton administration, using a fast-tracked approval process. The FDA justified approval by reclassifying abortion as a “serious or life-threatening illness” and mifepristone as a “meaningful therapeutic benefit.” In a 2008 report, the Governmental Accountability Office (GAO) noted the medical community’s widespread criticism of the basis for mifepristone’s approval.
“Critics have argued that unwanted pregnancy should not be considered a serious or life-threatening illness,” stated the GAO report.
Mifepristone’s efficacy and safety are dubious. The drug’s usage has been linked to hundreds of cases of infections and death, if not more. Government studies have estimated adverse effects of the drug occurring in as many as one in five women. The FDA also failed to convince the New Orleans court of the drug’s safety.
“[I]n loosening mifepristone’s safety restrictions, [the] FDA failed to address several important concerns about whether the drug would be safe for the women who use it,” read the majority opinion.
Yet, state leaders have advocated for access to the abortion drug. Attorney General Kris Mayes’ office claims the drug is “incredibly safe” and that restrictions on it are “unnecessary.”
In June, Hobbs issued an executive order usurping county attorneys’ authority over prosecuting abortion law violations.
In March, Mayes encouraged pharmacies to give out abortion pills. In May, Mayes joined an amicus brief to advocate for the upholding of mifepristone’s FDA approval.
Hours after the circuit court ruling, Mayes’ new Reproductive Rights Unit issued guidance on how individuals can hide their data, such as internet history and communications, when seeking abortions. The new unit is headed by deputy solicitor general Hayleigh Crawford.
The attorney general didn’t issue a direct response to this week’s ruling, but the data privacy guidance and corresponding meeting appeared to be an indirect response of sorts.
Featured guests at the meeting included:
- Chris Love, board member and senior advisor for Planned Parenthood Advocates of Arizona, and attorney at Kewenvoyouma Law;
- Sheena Chiang, co-chair of the Planned Parenthood Arizona Board of Directors, and attorney for the Maricopa County Legal Defender’s office;
- Jodi Liggett, founder of the progressive think tank and advocacy group Arizona Center for Women’s Advancement, former deputy chief of staff for Phoenix Mayor Kate Gallego, former vice president of external affairs and executive director for Planned Parenthood of Arizona, former senior policy advisor for Phoenix Mayor Greg Stanton, former CEO of Arizona Foundation for Women, and former policy advisor for former Gov. Jane Hull;
- Bré Thomas, CEO of Affirm Sexual and Reproductive Health For All, former Arizona Department of Health Services manager and senior policy advisor, former Arizona Department of Economic Security executive assistant to the deputy director, and former women’s health policy advisor for former Gov. Janet Napolitano;
- Cadey Harrel, doctor and founder of Agave Community Health and Wellness;
- Tonya Irick, director of abortion clinic Family Planning Associates Medical Group
Corinne Murdock is a reporter for AZ Free News. Follow her latest on Twitter, or email tips to corinne@azfreenews.com.
by Daniel Stefanski | Apr 17, 2023 | News
By Daniel Stefanski |
Arizona has been one of the nation’s most-ardent pro-life states, but its new Democrat Attorney General is seeking to quickly reverse that standing as she reacts to recent cases in the federal court system.
Last Friday, United States District Judge Matthew J. Kacsmaryk, who was appointed by former President Donald Trump, issued an order in Alliance for Hippocratic Medicine, et al. v U.S. Food and Drug Administration, granting a motion to stay “the effective date of the Food and Drug Administration’s (FDA) September 28, 2000 Approval of mifepristone and all subsequent challenged actions related to that approval – i.e., the 2016 Changes, the 2019 Generic Approval, and the 2021 Actions.”
Yet the same day, United States District Judge Thomas O. Rice, who was appointed by former President Barack Obama, issued an order in State of Washington, et al. v. U.S. Food and Drug Administration, et al., preliminarily enjoining the FDA and other defendants from “altering the status quo and rights as it relates to the availability of Mifepristone under the current operative January 2023 Risk Evaluation and Mitigation Strategy under 21 U.S.C. 355-1 in Plaintiff States.”
The plaintiffs in Judge Rice’s order were Washington, Oregon, Arizona, Colorado, Connecticut, Delaware, Illinois, Michigan, Nevada, New Mexico, Rhode Island, Vermont, Hawaii, Maine, Maryland, Minnesota, Pennsylvania, and the District of Columbia.
Judge Kacsmaryk stayed his own order for seven days “to allow the federal government time to seek emergency relief from the United States Court of Appeals for the Fifth Circuit.” Judge Rice’s order went into effect immediately for the plaintiff states.
Arizona Attorney General Kris Mayes previously joined the Washington case in February, stating that the lawsuit “asserts that the FDA exceeded its authority by continuing its unnecessary and extremely burdensome restrictions on mifepristone,” and it “asks the court to find the FDA’s REMS (Risk Evaluation & Mitigation Strategies) restrictions unlawful and to bar the federal agency from enforcing or applying them to mifepristone.”
After Friday’s two judicial orders, Mayes assured her fellow Arizonans “that legal access to the drug (mifepristone) remains available for providers and patients in this state.” She promised that her office would join other states in filing an amicus brief to oppose Judge Kacsmaryk’s ruling, which came Monday. The court filing from several attorneys general across the country urged the U.S. Court of Appeals for the Fifth Circuit “to stay pending appeal the district court’s ruling.” Mayes said that “Judge Kacsmaryk’s outrageous and appalling ruling, if allowed to stand, would upend decades of scientific research and established legal principles.”
A three-judge panel quickly considered the appeal and decided that “the statute of limitations bars plaintiffs’ challenges to the Food and Drug Administration’s approval of mifepristone in 2000.” However, the judges noted that the plaintiffs’ arguments brought before the district court in “2016 and subsequent years” were timely. The FDA’s changes from 2016-on were as follows: “increased gestational age to 70 days (from 50 days); reduced required in-person office visits to one (from three), allowed non-doctors to prescribe and administer mifepristone; and eliminated reporting of non-fatal adverse events.” In 2021, the FDA also announced “’enforcement discretion’ to allow mifepristone to be dispensed through the mail during COVID-19.”
After the decision from the Appeals Court panel, Kristen Waggoner, the CEO and President for Alliance Defending Freedom, tweeted, “Last night’s Fifth Circuit decision is a step forward for the rule of law. Critical safeguards removed by the @US_FDA will be restored and abortion by mail will end. The FDA put politics over science when it unlawfully approved dangerous chemical abortion drugs. It has evaded legal responsibility for years and has jeopardized the health of women and girls. While there is still work to do to hold the FDA accountable for its lawlessness, girls and women are safer today.”
On Thursday, Attorney General Mayes “provided a summary of the legal status of mifepristone in Arizona” – as it stood at the moment. Mayes admitted that “this is a fast-moving situation, and we are likely to see further court orders in the coming days and weeks.” She vowed to “use every tool at our disposal to fight back against rulings from extremist judges seeking to interfere with the rights of individuals to make their own personal medical decisions.” Her release broadcasted that “under Arizona law, patients in other states who need reproductive care can still travel to Arizona to receive care here.”
The case is expected to be expedited to the U.S. Supreme Court based on the conflicting rulings from the District Courts in Texas and Washington, and the updated decision from the U.S. Court of Appeals for the Fifth Circuit.
Daniel Stefanski is a reporter for AZ Free News. You can send him news tips using this link.
Page 1 of 11
